TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06643273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Description: Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.
Study: NCT06645015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI augmented risk-stratification
Description: A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
Study: NCT05983705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.
Description: The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.
Description: The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
Study: NCT05153317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination granules or tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules or tablets for oral administration.
Study: NCT06596759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: REDCap will be used to administer the Mayo Bloating Questionnaire (MBQ) and collect self-reported compliance to diaphragmatic breathing (DB) exercises over a 4 week follow up period. After completion of the MBQ, the patient will be taught DB techniques by an individual physical therapist face to face over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. Patients will receive a telephone call and electronic health record portal message to check progress and answer any questions. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing. The questionnaire will include prompts investigating perceived side effects and attitudes towards therapy, willingness to perform DB therapy, likelihood to attempt self-guided DB in the future, and if the participant would recommend the therapy to a friend.
Study: NCT05218434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-158
Description: Oral administrations of AX-158
Study: NCT06671301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSAI
Description: Holistic stress management program implementing the pillars of Lifestyle Medicine

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care without specific treatment
Study: NCT06675864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion
Study: NCT06674707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility Training with Foot mobilization.
Description: Agility training with foot mobilization with the frequency of 3 sets of 10 repetitions thrice per week for a total six weeks. Pre and post intervention values will be taken on 1st day and after six weeks. Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. TJM is a grade III Maitland technique and is applied with a high amplitude from the end range and 1s of vibration in the middle range of the joint through a linear motion to where tissue resistance is felt in the prone position, the patient is supported by a towel placed under the foot. Two sets of 5 min total were performed for 6weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Agility Training without Foot mobilization
Description: Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. Comprising of Hot pack and TENS for 10 minutes and Ultrasound for 5 minutes . Comprising of conventional exercises were given for 3 sessions per week for 6 weeks. It includes semi squat, quadriceps isometric, terminal knee extension with elastic band, terminal knee extension in supine position, and adductor squeeze in crook lying (squeeze the ball).
Study: NCT06673446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vestibular socket therapy
Description: atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vestibular socket therapy
Description: atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra
Study: NCT05319197

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study: NCT06675318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross training for quadriceps muscle of contralateral lower limb
Description: An isokinetic exercise program consisting of 20 sessions conducted five days a week. The program begins with five repetitions at a speed of 60°/s, followed by sets of 5-15 repetitions with incremental increases of 30°/s. Rest periods of 30 seconds were included between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps isometric exercises, along with hot pack and TENS for painful knee
Description: 10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps isometric exercises, along with hot pack and TENS for painful knee
Description: 10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee
Study: NCT06624995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chatbot education
Description: elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
Study: NCT06683677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula
Description: The intervention involves administering High-Flow Nasal Cannula therapy to extremely preterm infants immediately after birth.
Study: NCT06691438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: prostate biopsies with virtual reality hypnosis headset

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: prostate biopsies with virtual reality hypnosis headset
Study: NCT06690736

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CXCR4 PET/CT Imaging
Description: Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Study: NCT06356181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Maximus Training Device
Description: Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Respiratory Training Device
Description: Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
Study: NCT04591184

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Covigenix VAX-001 placebo
Description: Placebo vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covigenix VAX-001
Description: Active Covigenix VAX-001
Study: NCT04732468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD (Suspension for injection)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD (Suspension for injection)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
Study: NCT06300398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAMA-6
Description: IAMA-6 liquid suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAMA-6
Description: IAMA-6 liquid suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAMA-6
Description: IAMA-6 liquid suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-to-match IAMA-6 liquid suspension
Study: NCT04732468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD (Suspension for injection)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hAd5-SFusion+ N-ETSD (Oral capsule)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
Study: NCT06533072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group receiving infrared LED therapy
Description: Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
Study: NCT05868824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
Study: NCT05070962

Intervention type: OTHER
Intervention: clinical population
Description: or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.

Intervention type: OTHER
Intervention: clinical population
Description: or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
Study: NCT03437330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (Jardiance®)
Description: Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (Lantus®)
Description: insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
Study: NCT04732468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hAd5-SFusion+ N-ETSD (Oral capsule)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hAd5-SFusion+ N-ETSD (Oral capsule)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hAd5-SFusion+ N-ETSD (Oral capsule)
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
Study: NCT06689423

Intervention type: DEVICE
Intervention: Credo POCT Device
Description: Testing Credo's POCT device for respiratory viruses detection.
Study: NCT06466837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time intervention
Description: The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: The control group participants will receive six nursing consultations during the 3-month program period.
Study: NCT06241430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS
Description: Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
Study: NCT06474013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 Type 2.1
Description: The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
Study: NCT04783428

Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as part of this DMP

Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as part of this DMP

Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as part of this DMP
Study: NCT04681885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered bristles A
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tapered bristles A
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered bristles A
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered bristles B
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tapered bristles B
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered bristles B
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: End rounded bristles
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End rounded bristles
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: End rounded bristles
Description: Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
Study: NCT06211868

Intervention type: BEHAVIORAL
Intervention: Digital wearable and AI-human symbiotic lifestyle intervention
Description: Digital wearable and AI-human symbiotic lifestyle intervention
Study: NCT06251960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation with completely demineralized dentin graft
Description: socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation with partially demineralized dentin graft
Description: socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
Study: NCT06319053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbine-based insufflator
Description: The use of a turbine-based insufflator instead of a conventional insufflator
Study: NCT05775042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 injection
Study: NCT05147428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Educational materials on inappropriate prescribing and deprescribing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Educational materials on inappropriate prescribing and deprescribing.